We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics

0.4775 USD
-0.0275
5.45%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
0.4652
-0.0123
2.58%
1 day
-5.45%
5 days
-26.54%
1 month
-37.99%
3 months
-64.37%
6 months
-82.38%
Year to date
-97.47%
1 year
-97.84%
5 years
-100%
10 years
-100%
 

About: Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Employees: 29

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
8 days ago
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
-     Continued to advance the development of CLD-401 towards the clinic -      Presented new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026 -      Received $1.2 million gross proceeds from at-the-market registered direct offering -      Reduced general and administrative expenses by $1.0 million, or 39%, in the third quarter of 2026 versus the same period in the prior year SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today reported financial and operating results for the three months ended September 30, 2026, and reviewed recent business highlights. “Throughout the third quarter, Calidi continued to advance its RedTail platform for systemic and local delivery and redefine the potential of oncolytic viruses and genetic medicine,” said Eric Poma, Ph.D.
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
25 days ago
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform generated approximately 10 ng/mL of EpCAM-targeted TCE directly within tumors following IV delivery, without systemic administration of the TCE protein itself, turning the tumor into a localized TCE biofactory SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it presented two posters at the European Society for Medical Oncology (ESMO) Congress 2026 last week in Madrid. The presentations showcased new data from the Company's RedTail platform, a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Neutral
GlobeNewsWire
1 month ago
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. The presentations will showcase the Company's RedTail platform, a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Neutral
GlobeNewsWire
1 month ago
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American Company Guide (the "Company Guide")requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice also indicates that the Company is not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
Neutral
GlobeNewsWire
2 months ago
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company's common stock, in a registered direct offering, at a per share purchase price of $1.17.  The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions.
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Neutral
GlobeNewsWire
2 months ago
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Neutral
GlobeNewsWire
3 months ago
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
3 months ago
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarter of 2027 and its in situ T-cell engager (TCE) program.
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
Neutral
GlobeNewsWire
4 months ago
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) --  Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today recapped 2026 successes to date and provided an update on the Company's upcoming milestones.
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Neutral
GlobeNewsWire
4 months ago
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the “Reverse Stock Split”). The Company's common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of “CLDI.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 320703 507.
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Price charts implemented using Lightweight Charts™